JP7617036B2 - Ａｌｋ７結合タンパク質及びその使用 - Google Patents

Ａｌｋ７結合タンパク質及びその使用 Download PDF

Info

Publication number
JP7617036B2
JP7617036B2 JP2021570762A JP2021570762A JP7617036B2 JP 7617036 B2 JP7617036 B2 JP 7617036B2 JP 2021570762 A JP2021570762 A JP 2021570762A JP 2021570762 A JP2021570762 A JP 2021570762A JP 7617036 B2 JP7617036 B2 JP 7617036B2
Authority
JP
Japan
Prior art keywords
alk7
seq
amino acid
binding protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021570762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534514A5 (https=
JPWO2020243443A5 (https=
JP2022534514A (ja
Inventor
クノップ，ジョン
クマール，ラビンドラ
グリンバーグ，アシャ
サコ，ダイアン
カストングアイ，ロゼリン
ダゴン，ヨッシ
ベルク，ジョナサン
ジェイ． シャーキー，ネイサン
Original Assignee
アクセレロン ファーマ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセレロン ファーマ インコーポレーテッド filed Critical アクセレロン ファーマ インコーポレーテッド
Publication of JP2022534514A publication Critical patent/JP2022534514A/ja
Publication of JP2022534514A5 publication Critical patent/JP2022534514A5/ja
Publication of JPWO2020243443A5 publication Critical patent/JPWO2020243443A5/ja
Application granted granted Critical
Publication of JP7617036B2 publication Critical patent/JP7617036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021570762A 2019-05-30 2020-05-29 Ａｌｋ７結合タンパク質及びその使用 Active JP7617036B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854619P 2019-05-30 2019-05-30
US62/854,619 2019-05-30
PCT/US2020/035141 WO2020243443A1 (en) 2019-05-30 2020-05-29 Alk7 binding proteins and uses thereof

Publications (4)

Publication Number Publication Date
JP2022534514A JP2022534514A (ja) 2022-08-01
JP2022534514A5 JP2022534514A5 (https=) 2023-06-06
JPWO2020243443A5 JPWO2020243443A5 (https=) 2023-06-06
JP7617036B2 true JP7617036B2 (ja) 2025-01-17

Family

ID=73553930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570762A Active JP7617036B2 (ja) 2019-05-30 2020-05-29 Ａｌｋ７結合タンパク質及びその使用

Country Status (8)

Country Link
US (1) US12365736B2 (https=)
EP (1) EP3976656A4 (https=)
JP (1) JP7617036B2 (https=)
KR (1) KR20220016136A (https=)
CN (1) CN114245805A (https=)
AU (1) AU2020282764A1 (https=)
CA (1) CA3142147A1 (https=)
WO (1) WO2020243443A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7617036B2 (ja) 2019-05-30 2025-01-17 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合タンパク質及びその使用
JP2024532345A (ja) * 2021-09-03 2024-09-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 抗ａｃｖｒ２ａ抗体及びその使用
WO2025155971A1 (en) * 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185037A1 (en) 2016-04-22 2017-10-26 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
WO2019084249A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. ALK7 BINDING PROTEINS AND USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7617036B2 (ja) 2019-05-30 2025-01-17 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合タンパク質及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185037A1 (en) 2016-04-22 2017-10-26 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
WO2019084249A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. ALK7 BINDING PROTEINS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOGOSAWA, S., et al.，"Activin Receptor-Like Kinase 7 Suppresses Lipolysis to Accumulate Fat in Obesity Through Downregulation of Peroxisome Proliferator－Activated Receptor γ and C/EBPalpha."，DIABETES，2013年01月，Vol.62，pp.115-123，DOI: 10.2337/db12-0295

Also Published As

Publication number Publication date
EP3976656A4 (en) 2023-07-12
CN114245805A (zh) 2022-03-25
EP3976656A1 (en) 2022-04-06
US20220348685A1 (en) 2022-11-03
WO2020243443A1 (en) 2020-12-03
JP2022534514A (ja) 2022-08-01
AU2020282764A1 (en) 2021-12-02
KR20220016136A (ko) 2022-02-08
CA3142147A1 (en) 2020-12-03
US12365736B2 (en) 2025-07-22

Similar Documents

Publication Publication Date Title
US11708414B2 (en) ALK7 binding proteins and uses thereof
US12042524B2 (en) Activin type 2 receptor binding proteins methods of making them
JP7669291B2 (ja) Ａｃｔｒｉｉ結合性タンパク質及びその使用
US20240287196A1 (en) ALK7 Binding Proteins and Uses Thereof
JP7617036B2 (ja) Ａｌｋ７結合タンパク質及びその使用
HK40094995A (zh) Alk7结合蛋白及其用途
HK40003020B (en) Alk7 binding proteins and uses thereof
HK40003020A (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220118

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617036

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150